leadf
logo-loader
viewSensyne Health PLC
(
AIM:SENSFRA:DSH
)

Sensyne Health shares rise on COVID-19 test partnership with Excalibur

“This is another triumph for UK science and technology,” said Excalibur chief executive Sir Chris Evans.

Sensyne Health PLC - Sensyne Health shares rise on COVID-19 test partnership with Excalibur

Sensyne Health PLC (LON:SENS) shares gained 6.39% as it inked an exclusive licence and development agreement with Excalibur Healthcare Services, for the use of its MagnifEye system for use with Excalibur's proprietary lateral flow rapid COVID-19 diagnostic tests.

Excalibur’s antigen test has out-performed other competing tests in recent trials with its speed, sensitivity and reliability.

The test is approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.

Additionally, Excalibur will integrate MagnifEye into its products for global marketing to customers in both the public and private sectors. Sensyne will receive royalties on each test result, with a minimum guaranteed contract value.

READ: Sensyne launches coronavirus management algorithm

In the future, Excalibur will potentially use MagnifEye in other diagnostic tests for serology, cancer and other disease conditions.

"Through our laboratories in Cambridge, we have been working with Sensyne to optimise the application of MagnifEye with our rapid antigen COVID test,” said Professor Sir Chris Evans, Excalibur chief executive.

“The combination has significantly increased the sensitivity of the test and we believe makes it the most advanced and accurate antigen lateral flow test in the worldwide market today.

“This is another triumph for UK science and technology.”

Sensyne chief executive Lord Drayson, meanwhile, added: "The combination of Sensyne's clinical AI technology and Excalibur's test will, we believe, provide the most accurate diagnostic lateral flow test available in the world today. 

“This agreement reflects the UK's leadership position and expertise in life science and data science and underlines Sensyne's expertise in putting the AI inside a growing range of innovations.

“With increasing global demand for rapid, easy to use diagnostic testing across a range of conditions, this agreement has the potential to create significant value from this fast growing US$6bn market.

“Sir Chris's team at Excalibur has been established for more than 20 years and we are delighted to be working with them."

Quick facts: Sensyne Health PLC

Follow
AIM:SENS

Price: 145 GBX

Market Cap: £238.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

JD Sports gets angry while Melrose shareholders are more than happy

The FTSE 100 edged higher as investors looked forward to tomorrow’s US jobs data. BHP’s huge payout going ex- dividend was a drag but London’s blue-chip index was up six at 7,156 in early trades. Barratt Developments profits rebounded by 65% in its latest financial year as it added the...

2 weeks, 5 days ago

2 min read